Abbott Laboratories vs Eli Lilly
ABT and LLY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABT and LLY compare
Eli Lilly is the larger company, worth 7.3 times as much as Abbott Laboratories ($1.3T against $184B).
On earnings, Abbott Laboratories is cheaper: it trades at 34.1× trailing earnings, against 46.0× for Eli Lilly.
Eli Lilly grew revenue faster over the last twelve months (45.5% versus 8.1% for Abbott Laboratories).
Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with 11.6% at Abbott Laboratories.
Both pay dividends: Abbott Laboratories yields 2.4% and Eli Lilly 0.47%.
Eli Lilly scores higher on the StockData Score (20 against 14 for Abbott Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABT | LLY |
|---|---|---|
| Size and price | ||
| Market cap | $184B | $1.3T |
| Share price | $106.20 | $1417.54 |
| Change, 1 year | −14.7% | 74.2% |
| Change, 5 years | −14.6% | 435% |
| Beta (5Y) | 0.47 | 0.52 |
| Employees | 115K | 50K |
| StockData Score | ||
| Total score | 14 | 20 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 3 | 6 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 4 | 4 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 34.1× (better) | 46.0× |
| P/S | 3.9× (better) | 15.4× |
| P/B | 3.6× (better) | 33.1× |
| EV/EBITDA | 28.8× (better) | 37.3× |
| P/FCF | 23.5× | – |
| PEG | – | 0.93 |
| FCF yield | 4.3% | – |
| Fair value | $78.11 | $1125.50 |
| Margin of safety | −36.0% | −25.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.1% | 45.5% (better) |
| Revenue growth, 5Y average | 5.1% | 21.6% (better) |
| Net income growth (TTM) | −61.2% | 49.8% (better) |
| EPS growth (TTM) | −61.1% | 50.7% (better) |
| EPS growth, 5Y average | 8.3% | 27.6% (better) |
| Profitability | ||
| Gross margin | 56.6% | 83.6% (better) |
| Operating margin | 15.8% | – |
| Net margin | 11.6% | 31.9% (better) |
| FCF margin | 16.8% | – |
| Return on equity | 10.7% | 86.1% (better) |
| Return on invested capital | 7.9% | – |
| Financial health | ||
| Debt / equity | 0.64 (better) | 1.23 |
| Net debt / EBITDA | 3.68 | 1.21 (better) |
| Interest coverage | 9.6× | – |
| Current ratio | 1.38 | 1.39 (better) |
| Altman Z-score | 3.28 | 8.52 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.4% (better) | 0.47% |
| Payout ratio | 78.5% | 21.7% |
| Years of dividend growth | 3 | 9 (better) |
| Dividend growth, 5Y average | – | 15.2% |
| Buyback yield | 1.00% (better) | 0.44% |
| Shareholder yield | 3.4% (better) | 0.91% |
| Ownership | ||
| Held by institutions | 79.8% | 83.7% |
| Held by insiders | 0.50% | 10.4% |
| Insider net buying, 12 months | −$43.1M (better) | −$2.3B |
| Superinvestors holding | 2 | 3 (better) |
| Short interest, % of float | 0.79% | 0.83% |
Go deeper
- ABT stock overview
- ABT income statement
- ABT valuation and score
- LLY stock overview
- LLY income statement
- LLY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.